• Digoxin Workflows for Cardiac and Antiviral Research

  2026-08-26

  Digoxin supports two distinct research tracks: Na+/K+ ATPase-driven cardiac contractility studies and cell-type-specific inhibition of chikungunya virus infection. This guide links product handling, concentration design, controls, and troubleshooting to help researchers distinguish mechanism-specific effects from solvent, viability, and model artifacts.

• STAT5B, Myelin Repair and Parkinson’s Disease

  2026-08-25

  A 2025 Cells study identifies a DNMT3A–STAT5B–MBP regulatory axis linking epigenetic silencing in oligodendrocytes to myelin impairment, dopaminergic neuron loss, and motor dysfunction in Parkinson’s disease models. By combining single-nucleus transcriptomics with trajectory, methylation, promoter-binding, ultrastructural, and behavioral analyses, the work positions oligodendrocyte STAT5B as a mechanistically testable contributor to Parkinsonian pathology.

• Light-Inducible RNA Release for Regulated Gene Therapy

  2026-08-25

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic gene expression at the translation stage. By combining reversible optical control with AAV and cell-based delivery strategies, the authors demonstrate on-demand regulation in obesity and retinal neovascular disease models, highlighting a potential safety layer for chronic gene therapies.

• Reparixin A3752: Reliable CXCR1/2 Assays

  2026-08-24

  Learn how Reparixin (SKU A3752) can help laboratories dissect CXCR1/2-dependent signaling in viability, proliferation, cytotoxicity, and neutrophil migration workflows. This scenario-driven guide covers assay design, fresh-solution handling, data interpretation, and practical supplier selection.

• RRP Restores Lipid Metabolism in Hepatic HIRI

  2026-08-23

  The reference study identifies a lipid-centered mechanism by which Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury in mice and lipid-loaded hepatocytes. Its key contribution is linking AMPK activation to suppression of SCAP-SREBP2 cholesterol synthesis and stimulation of LXRα-dependent cholesterol efflux.

• Saracatinib (AZD0530) in Cancer Biology

  2026-08-22

  Saracatinib, also called AZD0530, is a research kinase inhibitor that targets Src family kinases and Abl. Product data support mechanistic studies of cancer cell proliferation inhibition, migration, signaling, and tumor growth inhibition in xenograft models, while the Reelin-SFK literature provides pathway context rather than direct saracatinib validation.

• Localized BDNF Release in Early NMJ Formation

  2026-08-21

  The reference study shows that muscle-derived BDNF is a spatially controlled regulator of early neuromuscular junction assembly, rather than only a diffusible trophic factor. By combining live-cell imaging, loss-of-function experiments, proteolytic perturbation, and muscle-specific knockout mice, the authors connect BDNF trafficking and localized processing with the formation of acetylcholine receptor clusters.

• Deferoxamine Mesylate: Iron Chelation in Research

  2026-08-21

  Deferoxamine mesylate is an iron-chelating agent used to reduce labile iron and investigate oxidative stress, hypoxia signaling, and tissue-protection phenotypes. Product information supports research use in ferrioxamine formation, HIF-1α stabilization, wound healing promotion, and selected tumor models, while a 2023 colorectal cancer study establishes that the compound was used as a reagent rather than proving it caused that study’s anticancer effects.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-20

  Masitinib (AB1010) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for controlled KIT, PDGFRα, and PDGFRβ inhibition in cancer, mastocytosis, and inflammatory disease models. It should not be selected for aqueous or ethanol-based workflows, broad-spectrum kinase studies, or clinical treatment decisions without appropriate independent evidence.

• METTL9 and Catalytic Antifungal Defense in the Gut

  2026-08-20

  Bao et al. identify secreted METTL9 as an intestinal epithelial defense factor that chemically modifies the Candida albicans zincophore PRA1, restricting fungal zinc acquisition, colonization, and dissemination. The study establishes a catalytic cross-kingdom mechanism distinct from conventional membrane-active or intracellular antifungal strategies and links reduced mucosal METTL9 with higher fungal abundance in inflammatory bowel disease.

• Chlorpromazine Workflows for Nanoparticle Uptake

  2026-08-19

  Use Chlorpromazine as a controlled pharmacological perturbation alongside cell-resolved nanoparticle uptake assays, while preserving the reference study’s size and PEG design logic. This workflow distinguishes receptor-linked cellular effects from hepatic sequestration and supports more reproducible antipsychotic research, dopamine receptor signaling, and nanomedicine experiments.

• Nicotinamide Adenine Dinucleotide (NAD+) Guide

  2026-08-19

  Nicotinamide Adenine Dinucleotide (NAD+) is a redox coenzyme and signaling substrate with roles in electron transfer, PARP activity, cyclic ADP-ribose synthesis, and sirtuin-mediated deacetylation. Current energy-stress evidence shows that AMPK can restrain ULK1-dependent autophagy in specific cellular contexts, so NAD+ research requires direct biochemical and pathway-level measurements rather than assumptions about increased autophagy.

• PD98059: Reliable MEK Inhibition in Cell Assays

  2026-08-18

  This scenario-driven guide explains how PD98059 (SKU A1663) can improve interpretation of viability, proliferation, apoptosis, and MAPK/ERK experiments. It combines product-handling data with recent mechanistic evidence and practical vendor-selection criteria for reproducible laboratory workflows.

• DAPI Workflows for Nuclear and Viability Readouts

  2026-08-18

  Build reproducible DAPI workflows for fixed-cell nuclear imaging, compromised-cell viability assessment, apoptosis-oriented morphology, and flow cytometry DNA staining. This guide connects the DAPI Solution (1 mg/mL) with a macrophage–nucleus pulposus cell model while separating practical assay recommendations from findings directly reported in the reference study.

• Erlotinib (NSC 718781) for EGFR Assays

  2026-08-17

  Erlotinib (NSC 718781) provides a practical chemical-genetic tool for measuring EGFR target engagement, growth inhibition, and apoptosis across cancer models. This guide connects EGFR assays with the emerging SCUBE3 biology and shows how to distinguish direct receptor blockade from broader tumor-microenvironment effects.

454 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page